 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JonesTrading analyst Sean Kim PhD maintained a Hold rating on Impel Pharmaceuticals (IMPL Research Report) today. The companys shares opened tod... JonesTrading analyst Sean Kim PhD maintained a Hold rating on Impel Pharmaceuticals (IMPL  Resear...

JonesTrading Reaffirms Their Hold Rating on Impel Pharmaceuticals (IMPL)

Impel Pharmaceuticals (IMPL Research Report) received a Hold rating and price target from JonesTrading analyst Sean Kim PhD today. The companys ... Impel Pharmaceuticals (IMPL  Research Report) received a Hold rating and price target from JonesTrading analyst...

JonesTrading downgrades Impel Pharmaceuticals (IMPL) to a Hold

U.S. stocks traded lower midway through trading, with the dropping over 50 points on Wednesday.
The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500, also fell, dropping, 0.09% to 4,451.55.
read more...

Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher

Thinking about buying stock in Workhorse Group, Canoo, Aurora Innovation, Plug Power, or Impel Pharmaceuticals? Thinking about buying stock in Workhorse Group, Canoo, Aurora Innovation, Plug Power, or Impel Pharmaceuticals? PR Newswire NEW YORK, July 5, 2023 NEW YORK, July 5, 2023 /PRNewswire...

Thinking about buying stock in Workhorse Group, Canoo, Aurora Innovation, Plug Power, or Impel Pharmaceuticals?

Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given the Prevalence of Pre-Existing Gastrointestinal Disorders Among Those Prescribed Trudhesa SEATTLE, June...

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa(R) at the 65th Annual Scientific Meeting of the American Headache Society

JonesTrading analyst Sean Kim PhD maintained a Buy rating on Impel Pharmaceuticals (IMPL Research Report) today and set a price target of $10.00.... JonesTrading analyst Sean Kim PhD maintained a Buy rating on Impel Pharmaceuticals (IMPL &#8211...

JonesTrading Sticks to Its Buy Rating for Impel Pharmaceuticals (IMPL)

Impel Pharmaceuticals ( NASDAQ:IMPL ) First Quarter 2023 Results Key Financial Results Revenue: US$4.37m (up 149% from...

Impel Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

Recap: Impel Pharmaceuticals Q1 Earnings

Trudhesa Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: ...

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, ...

Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It engages in the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs with an initial focus on diseases of the central nervous system. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.

Watchers	1,234
52-Wk Low	$0.285
52-Wk High	$6.31

Market Cap	$13.06M
Volume (M)	69,239.00
52-Wk High	$6.31
52-Wk Low	$0.285

IMPL Impel NeuroPharma Inc.

About

Feed

News

Earnings

Fundamentals